SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2002 Arrhythmia Research Technology, Inc. (Exact name of issuer as specified in its charter) Delaware 1-9731 72-0925679 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification Number) 25 Sawyer Passway Fitchburg, MA 01420 (Address of principal executive offices and zip code) (978) 345-5000 (Registrant's telephone number, including area code) Item 5. Other Events On November 4, 2002 Arrhythmia Research Technology, Inc. (the "Company") issued a press release announcing that at its Annual Meeting of Shareholders held November 1, 2002, Dr. Russell C. Chambers, a Director since 1982, and Mr. James E. Rouse, President and Chief Executive Officer, were elected as Directors of the Company for three-year terms. The Company also announced the appointment of Mr. David A. Garrison as Chief Financial Officer. Mr. Garrison recently joined the Company as Corporate Controller after nine years as Controller and Chief Financial Officer of H & R 1871, Inc., a privately held manufacturer of single-barrel shotguns. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits The press release of the registrant is attached as Exhibit 99.1 to this report. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fitchburg, Commonwealth of Massachusetts, on the 5th day of November, 2002. Arrhythmia Research Technology, Inc. /s/ James E. Rouse ------------------- President and Chief Executive Officer Exhibit Index Exhibit Description ------- ----------- 99.1 Press Release dated November 4, 2002